TELA Bio, Inc.

What they do

TELA Bio commercializes OviTex Reinforced Tissue Matrix products for hernia repair and abdominal wall reconstruction (ventral, inguinal, hiatal, laparoscopic, robotic) and OviTex PRS for plastic and reconstructive surgery. Products combine biologic and polymer materials, are sold primarily in the U.S. and Europe, and are manufactured exclusively by Aroa Biosurgery Ltd. The company also markets LiquiFix, a fixation product.

Revenue drivers

• OviTex hernia products — Main revenue source, includes configurations for ventral, inguinal, and hiatal hernia repair, plus OviTex LPR and OviTex IHR for laparoscopic and robotic procedures. Unit volume grew 12% year-over-year in Q2 2026, but price and mix headwinds pressured overall revenue.
• OviTex PRS (plastic and reconstructive surgery) — Second product portfolio, launched in the U.S. in May 2019. Q2 2026 revenue declined primarily due to lower PRS unit volumes, a key drag on total company growth.
• International sales (Europe) — Grew 26% year-over-year in Q2 2026, with continued momentum in several European markets. Partially offset domestic declines.
• LiquiFix — A fixation product that grew revenue by 39% year-over-year in Q2 2026, though smaller in absolute size than the OviTex lines.

Recent performance

Q2 2026 revenue was $19.3 million, down 4% from $20.2 million a year ago, due to lower OviTex PRS volumes and price/mix headwinds, partially offset by international growth. Gross margin improved to 72% from 70%, helped by a tariff refund and lower excess/obsolete inventory charges. Operating expenses were flat at $23.2 million, but net loss widened to $11.3 million from $9.9 million. Cash at June 30, 2026 was $30.4 million, with long-term debt of $56.1 million and negative shareholder equity of $15.9 million.

Strategy

Management has reorganized sales to reinforce cross-selling among field teams and aims to return to growth in the second half of 2026. They are upgrading talent in Market Access and Contracting to combat competitors' bundling practices. The company plans decisive action to extend cash runway and align cost structure with revenue. Prior focus on expanding OviTex product line (new configurations and clinical data generation) continues, including the April 2026 launch of OviTex RTM with PLGA reinforcement.

Risks

• Continued losses and need for capital — Net losses have persisted since inception ($38.8 million in 2025), and as of June 30, 2026, shareholder equity is negative and cash is only $30.4 million against $56.1 million long-term debt, requiring additional financing to sustain operations.
• Competitive bundling and pricing pressure — Largest competitors are bundling products and applying pricing pressure, which is compressing ASPs and limiting growth, prompting management to bolster market access efforts.
• Dependence on sole contract manufacturer — The company relies exclusively on Aroa Biosurgery Ltd for OviTex and OviTex PRS supply; any disruption could materially affect ability to meet demand.
• Potential Nasdaq delisting — An 8-K filed March 2026 disclosed a delisting notice or listing-rule failure, posing a risk to stock liquidity and investor confidence.

Outlook

The company withdrew full-year 2026 revenue guidance as the new CEO assesses the business. Management expects to improve PRS performance, accelerate hernia market share gains, and translate commercial productivity into sustainable growth. They also plan cost reductions to extend cash runway and expect to provide updated guidance in the future.